← Leaderboards
Thomas Briese
Wadsworth Center
$2,551,442
Attributed
$2,551,442
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $515.6K · FY2008–13$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,551,442 · 2
By mechanism
U54$2,551,442 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetySourceSpecificityCellsVaccinationVariantWest Nile VirusYeastsActivation-Induced Cytidine DeaminaseChikungunya VirusDisease OutbreaksEngineeringAntigensAutoimmune DiseasesHendra VirusHuman Monoclonal AntibodiesImmuneImmune ResponseSerumImmunoglobulin Somatic HypermutationImmunotherapeutic AgentBiologicalInfectionInfectious Disease Treatment
Grant awards (6)
Development of mAb therapeutics against biothreat and emerging diease agents$337,932
U54 · FY2013 · AI · contact PI
Development of mAb therapeutics against biothreat and emerging diease agents$402,448
U54 · FY2012 · AI · contact PI
Development of mAb therapeutics against biothreat and emerging diease agents$470,485
U54 · FY2011 · AI · contact PI
Development of mAb therapeutics against biothreat and emerging diease agents$515,568
U54 · FY2010 · AI · contact PI
Development of mAb therapeutics against biothreat and emerging diease agents$438,736
U54 · FY2009 · AI · contact PI
Velocimmune Platform$386,273
U54 · FY2008 · AI · contact PI